Document is current
Any future updates will be listed below
-
Authors
Posti, Jussi P. https://orcid.org/0000-0002-5925-5193
Sankinen, Matti
Sipilä, Jussi O. T. https://orcid.org/0000-0003-0183-9054
Ruuskanen, Jori O.
Rinne, Jaakko
Rautava, Päivi
Kytö, Ville
- License Information
-
More Information
Article History
Received: 4 December 2018
Accepted: 18 March 2019
First Online: 1 April 2019
Competing Interests
: Jussi P. Posti has received speaker’s fees from Orion corporation and Finnish Medical Association and a travel grant from Stryker. Matti Sankinen has received travel grants and congress fee covering (Zimmer-Biomet, Baxter, Medtronic, Stryker, Aesculap/B. Braun, DePuy Synthes, Skulle Implants, Innosurge). Jussi O.T. Sipilä has received honoraria (Pfizer, Merck), a consultancy fee (Norio centre), travel grants and congress fee covering (Orion Corporation, Abbvie, Lundbeck, Merck Serono, Nordicinfucare, Sanquin) and holds shares (Orion Corporation). Jori O. Ruuskanen has received speaker fees (Sanofi-Aventis, Orion Pharma, Biogen Idec, UCB Pharma, Novartis, Roche, Merck, Genzyme, Bayer, TEVA), travel grants and congress fee covering (Baxter, Bayer, GSK, Merck Serono, Boehringer Ingelheim, UCB Pharma, Lundbeck, Biogen Idec, Roche), and a consultancy fee (Merck). Jaakko Rinne has no financial disclosures. Päivi Rautava has received travel grant (Roche and Merck). Ville Kytö has no financial disclosures.
